In 2013, CoMentis, Inc. and Anvyl, LLC announced the formation of Alpharmagen, a joint venture committed to discovering and developing novel modulators of the α7 nicotinic acetylcholine receptor (nAChR).
This joint venture leverages the experience both companies have in the CNS space and combines the CoMentis portfolio of α7 nAChR agonists and Anvyl’s preclinical portfolio of allosteric modulators. The α7 nicotinic acetylcholine receptor is believed to play a role in cognition and modulators of this receptor in the human brain are reported to have shown promise in Phase 2 clinical trials exploring cognitive disorders associated with schizophrenia and Alzheimer’s disease.
About Anvyl: Anvyl LLC is based in Irvine, CA and specializes in the development of drugs for serious neurologic and psychiatric disorders. Anvyl’s drug discovery approach uses targeted allosteric modulation of ion channels to correct disease. For more information about Anvyl, please visit the Company’s website at: www.anvylllc.com